AMPK Activators as a Drug for Diabetes, Cancer and Cardiovascular DiseaseMark Goodman1, Zhenling Liu1,2, Ping Zhu2 and Ji Li1*
- Corresponding Author:
- Ji Li
Department of Pharmacology and Toxicology
School of Medicine and Biomedical Sciences
State University of New York at Buffalo, 615 BRB
3435 Main Street, Buffalo, NY 14214, USA
E-mail: [email protected]
Received December 03, 2013; Accepted February 26, 2014; Published March 04, 2014
Citation: Goodman M, Liu Z, Zhu P, Li J (2014) AMPK Activators as a Drug for Diabetes, Cancer and Cardiovascular Disease. Pharmaceut Reg Affairs 3:118. doi: 10.4172/2167-7689.1000118
Copyright: © 2014 Goodman M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The cellular mechanisms of AMP-Activated Protein Kinase (AMPK) activators in the treatment and prevention of diabetes, cancer, and cardiovascular disease (Graphical abstract).